Li Guo

Li Guo


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2025 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
HZHuining Zhang
Huining Zhang
RGRuoyi Guo
Ruoyi Guo
YHYusen Han
Yusen Han
ZYZhichao Yao
Zhichao Yao
MQMoyuan Quan
Moyuan Quan
LGLi Guo
Li Guo
Introduction: Multiple sclerosis (MS) is a chronic and debilitating inflammatory disease of the central nervous system (CNS), characterized by demyelination and neurodegeneration. Emerging evidence implicates neutrophils in MS pathogenesis, particularly through processes like neutrophil extracellular traps (NETs) formation and degranulation, which may exacerbate inflammation and autoimmunity.Methods: RNA sequencing of peripheral blood neutrophils from MS patients and healthy controls identified differentially expressed genes (DEGs). Pathway enrichment and protein–protein interaction (PPI) analyses highlighted potential biomarkers, validated using reverse transcription quantitative PCR (RT-qPCR) and enzyme-linked immunosorbent assay (ELISA).Results: Our analysis identified 1,968 DEGs in neutrophils from MS patients, comprising 1,068 upregulated and 900 downregulated genes. Pathway enrichment analysis revealed significant involvement of immune processes, including antigen presentation, B and T cell receptor signaling, intracellular signaling cascades, and neutrophil degranulation. Notably, KEGG analysis highlighted a pivotal role for upregulated genes in neutrophil extracellular traps (NETs) formation, a process increasingly associated with autoimmunity. PPI network analysis pinpointed five key hub genes—LCN2, LTF, ELANE, CAMP, and CTSG—as central players in neutrophil-mediated immune modulation. Protein-level validation using ELISA confirmed elevated levels of LCN2, ELANE, CAMP, and CTSG, consistent with transcriptomic findings, further supporting their role as biomarkers. Subsequent RT-qPCR validation demonstrated robust diagnostic potential for these genes, with area under the curve (AUC) values of 0.952 (LCN2), 0.827 (LTF), 0.968 (ELANE), 0.950 (CAMP), and 0.862 (CTSG).Discussion: These findings uncover a previously underappreciated role for neutrophils in MS pathogenesis, driven by alterations in gene expression linked to immune modulation and NET formation. The identified biomarkers, particularly ELANE and LCN2, demonstrate strong diagnostic potential, offering a new avenue for non-invasive MS diagnostics. Beyond clinical utility, this study highlights the importance of neutrophil-driven immune responses in MS, providing mechanistic insights into the complex interplay between innate and adaptive immunity in demyelinating diseases. Furthermore, these findings suggest that targeting neutrophil-specific processes, such as NETs formation and degranulation, could mitigate inflammatory damage and provide novel therapeutic approaches for MS treatment. These results lay the groundwork for future studies exploring therapeutic strategies targeting neutrophil functions in MS.

17 November 2025 in Brain and Behavior
Verified
Journal Article
Open access
SSShuang Song
Shuang Song
BLBin Li
Bin Li
RGRuoyi Guo
Ruoyi Guo
YZYi Zhou
Yi Zhou
YXYumei Xue
Yumei Xue
LGLi Guo
Li Guo
Objective: To investigate the therapeutic effects of liraglutide, a glucagon‐like peptide‐1 receptor agonist, on clinical progression and splenic T‐cell subsets in experimental autoimmune encephalomyelitis (EAE), a murine model of multiple sclerosis. Methods: EAE was induced in C57BL/6 mice via myelin oligodendrocyte glycoprotein immunization. The mice were divided into three groups: healthy controls (n = 8), EAE (n = 10), and EAE + liraglutide (n = 10). The EAE + liraglutide treatment group received subcutaneous liraglutide (10 µg/kg every other day) starting at 8 days postimmunization. Body weight and disease score were monitored for 30 days, and part of the animals (n = 4 for each group) were sacrificed 20 days postimmunization for flow cytometry of splenocytes, and splenic T helper 1 (Th1) and regulatory T (Treg) cell proportions were analyzed. Results: Liraglutide significantly reduced maximum clinical scores (EAE 2.50 ± 0.41 versus EAE + liraglutide 1.75 ± 0.59, p = 0.005), but no significant differences in body weight were observed between the EAE and EAE + liraglutide groups. EAE induction decreased the proportion of splenic Treg cells (6.38% ± 0.72% versus control 10.55% ± 0.87%, p = 0.013), with liraglutide treatment showing no significant effect on Treg proportion relative to EAE alone (7.53% ± 1.54% versus 6.38% ± 0.72%, p = 0.975). However, the proportion of Th1 cells significantly increased after EAE induction (11.95% ± 1.58% versus control 6.05% ± 3.23%, p = 0.025), which was reduced by liraglutide (5.94% ± 2.53% versus EAE, p = 0.025). Conclusions: The present preliminary findings demonstrate that liraglutide alleviates EAE severity, probably through peripheral immunomodulatory effects of splenic T helper cells.

5 May 2025 in Brain and Behavior
Verified
Journal Article
Open access
SSShuang Song
Shuang Song
RGRuo-Yi Guo
Ruo-Yi Guo
JGJiangyuan Guo
Jiangyuan Guo
BLBin Li
Bin Li
YHYusen Han
Yusen Han
LGLi Guo
Li Guo
Objective: To investigate whether nicotinamide adenine dinucleotide (NAD+) supplementation can improve behavioral changes in a cuprizone‐intoxicated mouse model.Methods: Six‐week‐old C57BL/6J mice were divided into three groups: two were fed 0.2% cuprizone chow (cuprizone and cuprizone + NAD+ groups), and the other group was fed normal rodent chow (control group) for 4 weeks. The mice in the cuprizone + NAD+ group received 250 mg/kg/day NAD+ intraperitoneally once a day, while the other mice were administered saline simultaneously. Behavioral tests for spatial memory (Morris water maze and Y maze), locomotor ability (grip test and rotarod test), depression‐like behavior (open field test and tail suspension test), and exploratory behavior (open field test) were conducted.Results: In the probe test of the Morris water maze, the cuprizone group spent a significantly smaller proportion of time in the target quadrant than the control group did (16.32% vs. 31.66%, p = 0.006). However, supplementation with NAD+ increased the value (28.78% vs. 16.32%, p = 0.023). Similarly, in the Y maze test, the cuprizone group demonstrated a notably lower ratio of effective alterations compared to the control group (0.543 vs. 0.648, p < 0.001), and the cuprizone + NAD+ group presented an improved ratio compared with the cuprizone group (0.613 vs. 0.543, p = 0.021). Compared with the control group, cuprizone toxicity resulted in a decreased time to fall (169.10 vs. 247.60 s, p = 0.015) in the grip test, but NAD+ supplementation mitigated this effect (261.60 vs. 169.10 s, p = 0.003). There were no significant differences in the immobile time among groups in both the tail suspension test and the open field test, and there were also no significant differences in center distance in the open field test.Conclusions: Direct NAD+ supplementation improves the locomotor ability and spatial memory of cuprizone‐intoxicated C57BL/6J mice. However, NAD+ supplementation does not show significant effects on depressive and exploratory behavior of experimental mice.

3 June 2024 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Open access
YXYuzhu Xu
Yuzhu Xu
CLCuicui Liu
Cuicui Liu
QZQi Zhou
Qi Zhou
HGHongqiu Gu
Hongqiu Gu
YJYanan Jia
Yanan Jia
LGLi Guo
Li Guo
Background and objective: Our study aimed to evaluate the associations between platelet count (PC) and in-hospital outcomes for patients with stroke after rt-PA intravenous thrombolysis. Methods: We identified patients who had been hospitalized with a primary diagnosis of stroke and had received rt-PA intravenous thrombolysis from June 2015 to July 2019 at participating hospitals in the Chinese Stroke Center Alliance. PC measured before intravenous thrombolysis was categorized into the following four groups: severe thrombocytopenia (PC < 100 x 10(9)/L), mild thrombocytopenia (100 <= PC < 150 x 10(9)/L), normal PC (150 <= PC <= 450 x 10(9)/L), and thrombocythemia (PC > 450 x 10(9)/L). Outcomes were determined from clinical data collected during hospitalization. The primary clinical outcome was symptomatic intracranial hemorrhage (sICH). Secondary outcomes were mortality, bleeding events, gastrointestinal (GI) hemorrhage, and in-hospital stroke recurrence. We used multivariate logistic regression models to evaluate the associations between PC and outcomes. Results: We included 44,882 individuals with a median age of 66 years, of whom 34.7 % were female, 951 (2.1 %) had severe thrombocytopenia, 7218 (16.1 %) had mild thrombocytopenia, 36,522 (81.4 %) had a normal PC, and 191 (0.4 %) had thrombocythemia. Both severe and mild thrombocytopenia groups had higher risks of bleeding events (adjusted OR 1.30; 95 % CI,1.01-1.67; p = 0.045; adjusted OR 1.32; 95 % CI,1.19-1.46; p < 0.001) and sICH (adjusted OR 1.48;95 % CI,1.13-1.94; p = 0.005; adjusted OR 1.43;95 % CI,1.27-1.60; p < 0.001) than the normal PC group. Patients with 100 <= PC < 150 x 10(9)/L also had a higher risk of in-hospital stroke recurrence (adjusted OR 1.12; 95 % CI,1.02-1.22; p = 0.02). Conclusions: Intravenous thrombolysis brings a high risk of sICH given PC < 150 x 10(9)/L, especially PC < 100 x 10(9)/L. It indicated that PC < 100 x 10(9)/L is a reasonable contraindication to thrombolysis.